Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas.

Cancer discovery - 1 Jun 2016

Paik Paul K

Abstract excerpt

Mutations in EGFR stand as the archetype for somatic alterations that lead to oncogene addiction and that predict for response to targeted therapies. In this issue of Cancer Discovery, Konduri and colleagues report on a pair of novel oncogenic and actionable EGFR fusion events in a series of patients with lung adenocarcinomas, casting new light on this model gene. Cancer Discov; 6(6); 574-5. ©2016 AACRSee related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to EGFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Oncogenes

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 27261479
DOI: 10.1158/2159-8290.CD-16-0478
PMCID: PMC4894533

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas.PMID 27261479Read ↗

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature ReviewSemantic proximity Read ↗

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read ↗

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective AnalysisSemantic proximity Read ↗

Rare EGFRm NSCLC: More First-Line Options Emerge.Semantic proximity Read ↗

Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).Semantic proximity Read ↗

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.Semantic proximity Read ↗

Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.Semantic proximity Read ↗

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read ↗

Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangementsSemantic proximity Read ↗

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomicsSemantic proximity Read ↗

Compound<i>EGFR</i>mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.